INFLUENCE OF FINGOLIMOD ON NON-RESPIRATORY FUNCTIONS OF LUNGS IN ANTIPHOSPHOLIPID SYNDROME
Main Article Content
Abstract
Objective – the role of immunosuppressive mechanisms in the correction of respiratory system dysfunctions associated with autoimmune pathology (antiphospholipid syndrome).
The aim of the study was to study the effect of the immunosuppressive drug fingolimod on non-respiratory functions of the lungs in antiphospholipid syndrome.
Methods. The experiments were carried out on 70 white outbred male rats. The rats of the 1st group were administered with cardiolipin antigen (0.2-0.4 mg per animal every other day for 3 weeks) to simulate antiphospholipid syndrome. Antiphospholipid syndrom in animals of the 2nd group was combined with the administration of fingolimod (1 mg / kg). The 3nd (control) group consisted of rats, which were injected with vehicle (0.9% NaCl) according to the same scheme. The complex of explored biophysical and biochemical parameters included surfactant composition and activity, pulmonary water balance and blood supply, and nitroxydergic activity of the lung. Statistical analysis of the obtained results was carried out using the SPSS 22 program.
Results. We have found that, in experimental antiphospholipid syndrome, the biophysical properties of surfactant decreased simultaneously with lung hyperhydration and impaired nitroxydergic activity. Fingolimod restored the parameters of surfactant, water balance and nitroxydergic activity of the lung, altered in antiphospholipid syndrome.
Conclusion. The results of the study indicate the effectiveness of immunosuppression in restoration of non-respiratory functions of the lung revealed in simulated systemic autoimmune pathology, antiphospholipid syndrome.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Hunter SF, Bowen JD, Reder AT. The direct effects of fingolimod in the central nervous system: Implications for relapsing multiple sclerosis. CNS Drugs. 2016; 30: 135-147. DOI: 10.1007/s40263-015-0297-0
De Stefano N, Silva DG, Barnett MH. Effect of fingolimod on brain volume loss in patients with multiple sclerosis. CNS Drugs. 2017; 31(4): 289-305. DOI: 10.1007/s40263-017-0415-2
Ghezzi A, Chitnis T, Laflamme A, Meinert R, Häring DA, Pohl D. Long-term effect of Immediate versus delayed fingolimodtreatment in young adult patients with relapsing–remitting multiple sclerosis: pooled analysis from the FREEDOMS/FREEDOMS II trials. Neurol. Ther. 2019; 8(2): 461-475. DOI: 10.1007/s40120-019-0146-z
Urakova MA, Bryndina IG. The influence of fingolimod on surfactant and hemostasis-regulating activity of the lung in experimental autoimmune encephalomyelitis. Pathogenesis. 2020; 18 (4): 43-48. Russian (Уракова М.А., Брындина И.Г. Влияние финголимода на сурфактант и гемостаз-регулирующую активность лёгких //Патогенез. 2020. Т. 18, № 4. С. 43-48)
Bryndina IG, Urakova MA. Phospholipids of erythrocytes, blood plasma, surfactant and lung coagulation activity in experimental antiphospholipid syndrome. Medical immunology. 2015; 17(S): 122. Russian (Брындина И.Г, Уракова М.А., Лебедева Н.В. Фосфолипиды эритроцитов, плазмы крови, сурфактанта и коагуляционная активность лёгких при экспериментальном антифосфолипидном синдроме //Медицинская иммунология. 2015. Т. 17, № S. С. 122)
Papadopoulos Ch, Panopoulou M, Mylopoulou T, Mimidis K, Tentes I, Anagnostopoulos K. Cholesterol and phospholipid distribution pattern in the erythrocyte membrane of patients with hepatitis C and severe fibrosis, before and after treatment with direct antiviral agents: a pilot study. Maedica (Bucur). 2020. 15(2): 162-168. DOI: 10.26574/maedica.2020.15.2.162
Chen Z, Zhong M, Luo Y, Deng L, Hu Z, Song Y. Determination of rheology and surface tension of airway surface liquid: a review of clinical relevance and measurement techniques. Respiratory Research. 2019. 20(1): 274. DOI: 10.1186/s12931-019-1229-1
Chebotareva AA, Komarevtseva IA, Yusuf RM, Chernykh YuA, Vishnitskaya IA, Komarevtseva EV, et al. Metabolites of nitric oxide in tissues, blood serum, mononuclear and mesenchymal stem cells. Man and his Health. 2016; (2): 90-95. Russian (Чеботарева А.А., Комаревцева И.А., Юсуф Р.М., Черных Ю.А., Вишницкая И.А., Комаревцева Е.В. и др. Метаболиты оксида азота в тканях, сыворотке крови, мононуклеарных и мезенхимальных стволовых клетках //Человек и его здоровье. 2016. № 2. С. 90-95)
Urakova MA, Bryndina IG. Surfactant in the water balance of the lungs after intracerebralhemorrage in conditions of capsaicin blocade of the vagusnerv. Neuroscience and Behavioral Physiology. 2016; 46(6): 639-643
Al-Saiedy M, Tarokh A, Nelson S, Hossini K, Green F, Ling Ch-Ch. The role of multilayers in preventing the premature buckling of the pulmonary surfactant. Biochim Biophys Acta Biomembr. 2017; 1859(8): 1372-1380. DOI: 10.1016/j.bbamem. 2017.05.004
Scaccabarozzi D, Deroost K, Lays N, Salè F.O., Van den Steen PhE, Taramelli D. Altered lipid composition of surfactant and lung tissue in murine experimental malaria-associated acute respiratory distress syndrome. PLoS One. 2015; 10(12): e0143195. DOI: 10.1371/journal.pone.0143195
Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis. Neurotherapeutics. 2017: 14(4); 859-873. DOI: 10.1007/s13311-017-0565-4
Huang Z, Liu H, Zhang X, Wen G, Zhu Ch, Zhao Y. Transcriptomic analysis of lung tissues after hUC-MSCs and FTY720 treatment of lipopolysaccharide-induced acute lung injury in mouse models. Int. Immunopharmacol. 2018; (63): 26-34. DOI: 10.1016/j.intimp.2018.06.036